Horizon / Plein textes La base de ressources documentaires de l'IRD

IRD

Publications des scientifiques de l'IRD

Cames Cécile, Pascal Léa, Ba A., Mbodj H., Ouattara B., Diallo N. F., Msellati Philippe, Mbaye N., Signate H. S., Blanche S., Diack A., MAGGSEN Cohort Study Group (collab.). (2018). Low prevalence of lipodystrophy in HIV-infected Senegalese children on long-term antiretroviral treatment : the ANRS 12279 MAGGSEN Pediatric Cohort Study. BMC Infectious Diseases, 18, art. 374 [9 p.]. ISSN 1471-2334

Fichier PDF disponible http://horizon.documentation.ird.fr/exl-doc/pleins_textes/divers18-09/010073721.pdf

Lien direct chez l'éditeur doi:10.1186/s12879-018-3282-7

En Libre Accès sur HAL http://www.hal.inserm.fr/inserm-01857856

Titre
Low prevalence of lipodystrophy in HIV-infected Senegalese children on long-term antiretroviral treatment : the ANRS 12279 MAGGSEN Pediatric Cohort Study
Année de publication2018
Type de documentArticle référencé dans le Web of Science WOS:000440969500009
AuteursCames Cécile, Pascal Léa, Ba A., Mbodj H., Ouattara B., Diallo N. F., Msellati Philippe, Mbaye N., Signate H. S., Blanche S., Diack A., MAGGSEN Cohort Study Group (collab.).
SourceBMC Infectious Diseases, 2018, 18, p. art. 374 [9 p.]. p. art. 374 [9 p.] ISSN 1471-2334
RésuméBackground: The long-term benefits of antiretroviral treatment (ART) are associated with metabolic complications, especially lipodystrophy, which has been well described among HIV-infected adults and children on ART in developed settings. Specifically, stavudine, and to a lesser extent zidovudine and protease inhibitors (PI), have been consistently implicated in the development of lipodystrophy. In 2006, following advice from the WHO, Senegal began phasing out stavudine from first-line ART. The objectives of this cross-sectional analysis are to assess and identify risk factors affecting the prevalence of lipodystrophy in Senegalese children and adolescents on long-term ART participating in a cohort study. Methods: Lipodystrophy was clinically assessed in two- to 18-year-old children on ART for at least six months and with no concurrent severe acute malnutrition. Risk factors for lipodystrophy were identified using stepwise multivariable logistic regression. Explanatory variables included clinical and personal data, immunovirologic status, and therapeutic history. Results: Overall, 254 children were assessed for lipodystrophy. The median age was 10.9 years (IQR: 8.1-142) and the median duration on ART was 54 months (32-84). Only 18% had been previously treated with stavudine, with a median treatment duration of 8 months (5-25). Ongoing treatment included 76% of children receiving zidovudine (median duration of 48 months (26-74)) and 27% receiving PI (lopinavir/ritonavir; median duration of 49 months (23-59)). Mild signs of lipodystrophy were observed in 33 children (13%): 28 with lipoatrophy, 4 with lipohypertrophy and one with combined type. Boys were more likely to present with lipoatrophy than girls (aOR: 4.3, 95% CI: 1.6-11.7). Children previously treated with stavudine for >= 1 year had a greater risk for lipoatrophy than those never exposed (3.8, 1.0-14.0), although the association was weak. There was no association between lipodystrophy and age or current or cumulative treatment with lopinavir/ritonavir or zidovudine. Conclusions: We report low prevalence of mild lipodystrophy in children and adolescents on long-term ART receiving a stavudine-sparing regimen. These findings are reassuring for clinicians in low-income settings where zidovudine is massively prescribed and lopinavir/ritonavir is the only widely available PI.
Plan de classementEntomologie médicale / Parasitologie / Virologie [052] ; Santé : généralités [050]
Descr. géo.SENEGAL
LocalisationFonds IRD [F B010073721]
Identifiant IRDfdi:010073721
Lien permanenthttp://www.documentation.ird.fr/hor/fdi:010073721

Export des données

Disponibilité des documents

Télechargment fichier PDF téléchargeable

Lien sur le Web lien chez l'éditeur

Accès réservé en accès réservé

HAL en libre accès sur HAL


Accès aux documents originaux :

Le FDI est labellisé CollEx

Accès direct

Bureau du chercheur

Site de la documentation

Espace intranet IST (accès réservé)

Suivi des publications IRD (accès réservé)

Mentions légales

Services Horizon

Poser une question

Consulter l'aide en ligne

Déposer une publication (accès réservé)

S'abonner au flux RSS

Voir les tableaux chronologiques et thématiques

Centres de documentation

Bondy

Montpellier (centre IRD)

Montpellier (MSE)

Nouméa

Papeete

Niamey

Ouagadougou

Tunis

La Paz

Quito